GM 1 -and GD 1a -like ganglioside mimicry in Campylobacter jejuni lipooligosaccharide (LOS) is considered to be involved in the pathogenesis of Campylobacter-induced Guillain-Barré syndrome (GBS). Compared with gastroenteritis-related isolates, GBS-related C. jejuni isolates were strongly associated with the expression of GD 1a -like mimicry. The presence of a few genes involved in LOS ganglioside mimicry, cst-II, cgtA, and cgtB, was also associated with GBS-related strains. GD 1a -like epitope expression may be an important virulence phenotype associated with the risk of developing GBS following campylobacter infection.
Guillain-Barré syndrome (GBS) is an acute, immune-mediated, postinfection disorder affecting the peripheral nervous system and is strongly associated with Campylobacter jejuni gastrointestinal (GI) infection (13) . Expression of gangliosidelike mimicry in the outer core lipooligosaccharide (LOS) and development of an immune response in the host that crossreacts with ganglioside-rich targets in the peripheral nerve are considered to be involved in the pathogenesis of Campylobacter-induced GBS (21) . Anti-GD 1a antibodies are associated with the axonal (acute motor axonal neuropathy [AMAN]) form of GBS, whereas anti-GM 1 antibodies are seen in both AMAN and demyelinating (acute inflammatory demyelinating polyneuropathy [AIDP]) forms (12) . Both AIDP and AMAN are associated with C. jejuni infection; however, patients with GBS following Campylobacter infection may be more likely to have axonal neuropathy (11, 12, 26, 28) .
To determine whether GD 1a -like mimicry is specifically expressed in C. jejuni from patients with GBS, we analyzed a collection of isolates from GBS and enteritis (GI infection) patients for expression of both GD 1a -and GM 1 -like mimicry.
(This work was presented in part at the 11th International Workshop on Campylobacter, Helicobacter and Related Organisms, Freiburg, Germany, 1 to 5 September 2001.)
Isolates listed in Table 1 were collected from a variety of worldwide sources and were previously studied by multilocus enzyme electrophoresis and for GM 1 -like mimicry (5, 23) . The isolates from GBS patients are likely to represent both AMAN and AIDP forms of GBS. However, information on the type of GBS was available from only a limited number of patients and is noted in Table 1. GM 1 -like and GD 1a -like mimicries were determined using a dot blot assay that was validated for the detection of GM 1 -like mimicry, as described previously (24) . GM 1 -like mimicry was detected using cholera toxin subunit B, which was labeled with horseradish peroxidase (Sigma, St. Louis, Mo.) and used at a concentration of 0.105 g/ml. The GD 1a -like epitope was detected using an anti-GD 1a monoclonal antibody (clone, Gg101; isotype, immunoglobulin G1) produced in knockout mice defective in the production of endogenous complex gangliosides and characterized previously by Lunn et al. (17) . Purified antibody was labeled with horseradish peroxidase as described by McIlhinney et al. (18) and used at a concentration of 0.035 g/ml. The GD 1a binding assay was validated using control strains of known ganglioside mimicry, and binding assays using 12 different blots of each reference strain were used to calculate confidence intervals (CI). There was clear separation of binding between C. jejuni HS:3 (ATCC 43431), which does not mimic gangliosides, and the serotype reference strain (serostrain) HS:19 (ATCC 43446), which exhibits both GM 1 -and GD 1a -like mimicry (24) isolates from GBS patients (n ϭ 17) were associated with GD 1a expression significantly more often than GI infection-associated HS:19 isolates (88.2 versus 30.6%; P ϭ 0.0003; OR, 17.05; CI, 2.89 to 130.72). For isolates of serotypes other than HS:19, GBS-associated isolates (n ϭ 11) were also associated with GD 1a expression significantly more often than GI serotypes (63.6 versus 11.1%; P ϭ 0.0008; OR, 14.00; CI, 2.44 to 91.03).
Also, we examined whether GD 1a -like expression was independent of GM 1 -like mimicry. Eight of 28 GBS (28.6%) isolates and 11 of 81 GI (13.6%) isolates expressed both GM 1 - Using PCR, we examined the presence of core LOS genes, cgtA, cgtB, and cst-II, associated with ganglioside mimicry in GBS-and GI infection-related C. jejuni isolates. Primer sets for each of the genes were developed based on previously published sequences (6, 15) . The primers for cgtA were CgtAUp (5ЈATA CGG GAG GGG CAT AAA G3Ј) and CgtADn (5ЈATA AGC AAG CAA TCT CCT GGT T3Ј) (527 bp). The cgtB primers were CgtBUp (5ЈAGA GCA AGA TAT GAA GGT GTG AA3Ј) and CgtBDn (5ЈAAA CCA ACT GCA ACT CTT GAA T3Ј) (502 bp). Two primer sets were used to detect cstII based on the HS:2 (NCTC11168) and HS:19 (OH4384) sequences reported by Gilbert et al. (6) . The primers used for cstII from HS:19 were Cst-IIUp (5ЈGTT ATT ATT GCT GGA AAT GGA CCA AGT 3Ј) and Cst-IIDn (5Ј ACA TAT AGA CCC CTG AGG TAA TTC TTT GAT3Ј) (400 bp), and the primers used for HS:2 were Cst-IIUp (5ЈTTG GTA TGC GGT AAT GGA CCT A3Ј) and Cst-IIDn (5ЈCAG AGC CAC AGC TGT AGC ACA 3Ј) (417 bp). Amplification using either cstII primer was indicative of the presence of the cstII gene. As a control for each bacterial DNA preparation, waaC, a conserved heptosyltransferase gene involved in LOS biosynthesis, was also amplified.
The presence of the three genes cst-II, cgtA, and cgtB was strongly associated with GBS-related isolates, unlike with GI isolates (82.1 versus 45.7%; P ϭ 0.001; OR, 5.47; CI, 1.74 to 18.34). There was no difference between GBS-and GI infection-related HS:19 isolates, as 98.1% of all HS:19 isolates contained these genes. However, GBS-related non-HS:19 isolates were more likely to contain these genes (54.5%) than were GI infection-related non-HS:19 isolates (2.2%) (P ϭ 0.001).
The role of ganglioside-like mimicry in eliciting pathogenic host immune responses is not fully understood, but patients with GBS are more likely to mount a host response to these mimics than are patients with GI disease only (29, 33) . C. jejuni strains have been shown to exhibit various types of ganglioside mimicry, including expression of GM 1 -, GM 2 -, GM 3 -, GD 1a -, GD 1b , GD 2 -, GD 3 -, and GT 1a -like structures (20) . In the present study, we examined both GM 1 -and GD 1a -like expression in GBS-and GI infection-associated C. jejuni isolates that were collected from all over the world. GM 1 -like mimicry was found not to be specific to isolates from either group of patients, which is consistent with our previous findings on the distribution of GM 1 mimicry in U.S. diarrheal isolates (24) . Likewise, a detailed structural analysis of C. jejuni HS:19 isolates associated with GBS or GI infection showed that both could express GM 1 mimicry (19) . Other studies have examined small numbers of isolates for the presence of ganglioside-type mimicry (25, 27, 31, 32, 36, 37) ; however, none have adequately assessed differences among GBS-and diarrhea-related strains.
Anti-GD 1a antibodies are highly associated with the AMAN form of GBS and are usually not generally produced in patients with AIDP (2, 12, 39) . Other antibodies, including antiGalNAc-GD 1a and anti-GD1b antibodies, have also been found to be associated with AMAN development (26) . Using a specific monoclonal antibody directed against GD 1a , we showed that expression of GD 1a -like mimicry was strongly associated with GBS-related isolates. Moreover, GBS-related isolates of the HS:19 serotype and non-HS:19 serotypes were significantly more likely to express the GD 1a -like epitope than were GI infection-related isolates. The association of GD 1a expression with GBS-related isolates was independent of GM 1 -type mimicry. Various C. jejuni HS serotypes have been isolated from patients with GBS, and some studies suggest that serotype HS:19 is overrepresented among patients with GBS in certain geographic locations but not in others (22) . These findings suggest that expression of GD 1a may be a serotype-independent property linked to the ability of C. jejuni to induce pathogenic antibodies in susceptible hosts.
There may also be quantitative differences in the amounts of GD 1a expressed, as suggested by the observation that the HS:4 serotype expresses a 9:1 ratio of GD 1a moieties to GM 1 moieties, compared to a 1:1 ratio for the HS:19 serostrain (1). The expression of GD 1a -like mimicry in GBS-related isolates does not rule out the possibility that other types of mimicry may be involved in the pathogenesis of Campylobacter-induced GBS. In preliminary studies using previously described techniques (27) , thin-layer chromatography immunostaining of several isolates with anti-GD 1a binding in the intermediate range suggest that GD1b-like mimicry may also be present (data not shown and reference 24).
While a GD 1a -like epitope was preferentially expressed in GBS-related isolates, some GI infection-related isolates expressed this epitope as well. The presence of this epitope, therefore, is not alone responsible for causing GBS. Host genetic susceptibility to developing GBS following exposure to a strain with this virulence phenotype is likely to be a critical factor (30, 35) .
The genetic basis for ganglioside-type mimicry has been studied only recently, and it is clear that the mechanisms for producing ganglioside-like structures in LOS are complex and on November 9, 2017 by guest http://iai.asm.org/ undergo phase variation (7, 9, 10, 15, 16) . We did not study the degree of phase-variable GD 1a expression in this study. Nevertheless, it is possible that phase-variable rates of GD 1a expression differ between GBS-and GI infection-related isolates. A few genes, cst-II, cgtA, and cgtB, appear to be critical in C. jejuni ganglioside mimicry expression (7, 9, 10, 15, 16) . In particular, cst-II (␣-2,3 and/or ␣-2,3/␣-2,8 sialyltransferase) has been shown to be involved in the addition of a terminal sialic acid residue that forms the GD 1a epitope (6) . The cgtA gene product, ␤1,4-N-acetylgalactosyltransferase, and the cgtB gene product, ␤1,3-galactosyltransferase, add the substrates for sialylation to the LOS backbone. We compared GBS-and GI infection-related isolates for the presence of these three genes and found that they were more strongly associated with GBS-related isolates than with uncomplicated GI isolates and that they were highly associated with the HS:19 serotype. The uniform presence of these genes in HS:19 isolates is not totally surprising since this serotype is highly clonal and infection with HS:19 is associated with an increased risk of GBS (22, 23) . Of particular interest is the observation by Gilbert et al. (8) that a GBS-related HS:2 isolate was shown to possess the HS:19 LOS gene cluster, suggesting that this gene cluster may confer unique, still to be completely defined, virulence properties involved in GBS pathogenesis.
Molecular analysis of C. jejuni isolates from GBS and GI patients has been unable to differentiate between GI infectionrelated and GBS-related isolates (3) (4) (5) 23) . The cst-II gene was found previously to be associated with a small number of GBS-related strains by van Belkum et al. (34) . In contrast, the present study clearly identified a phenotype strongly associated with GBS-related isolates. The lack of relevant animal models has hampered studies of the role of ganglioside-like mimicry in inducing GBS; however, the recent description of the development of nerve pathology in rabbits immunized with gangliosides may be applicable to studies of Campylobacter in the near future (14, 38) .
